News
February 9, 2023
Matisse Pharmaceuticals appoints Kees Groen and Marcel Jacobs to Board of Directors and Management Board.
Read more
September 7, 2022
Matisse Pharmaceuticals about to start third dose level in a Phase I/IIa study with its lead compound M6229 in septic patients.
Read more
November 10, 2021
Approval from the Dutch Health Authorities to initiate a Phase I study with Matisse Pharmaceuticals' lead compound M6229 in sepsis.
Read more
March 1, 2020
Matisse Pharmaceuticals raises financing for its phase I/IIa clinical trial treating patients suffering from sepsis.
Read more